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Acomprehensive genetic classiﬁcation of adult acute lymphoblastic leukemia
(ALL): analysis of the GIMEMA0496 protocol
Marco Mancini, Daniela Scappaticci, Giuseppe Cimino, Mauro Nanni, Valentina Derme, Loredana Elia, Agostino Tafuri, Marco Vignetti,
Antonella Vitale, Antonio Cuneo, Gianluigi Castoldi, Giuseppe Saglio, Fabrizio Pane, Cristina Mecucci, Andrea Camera,
Giorgina Specchia, Alessandra Tedeschi, Francesco Di Raimondo, Giuseppe Fioritoni, Francesco Fabbiano, Filippo Marmont,
Felicetto Ferrara, Nicola Cascavilla, Giuseppe Todeschini, Francesco Nobile, Maria Grazia Kropp, Pietro Leoni,
Antonio Tabilio, Mario Luppi, LucianaAnnino, Franco Mandelli, and Robin Foa `
The Gruppo Italiano Malattie Emato-
logiche dell’Adulto (GIMEMA) 0496 proto-
col, through the central handling of bone
marrow samples at presentation, allowed
us to combine cytogenetic and molecular
information on a large series of adults
with acute lymphoblastic leukemia (ALL)
treated homogeneously, enabling us to
deﬁne as broadly as possible their ge-
netic proﬁle and to determine the impact
on outcome of the cytogenetic-molecular
signature. Of 414 patients centrally pro-
cessed, 325 were considered for the cat-
egorizationintothefollowingcytogenetic-
molecular subgroups: normal, t(9;22)/
BCR-ABL, t(4;11)/MLL-AF4, t(1;19)/E2A-
PBX1, 9p/p15-p16 deletions, 6q deletions,
miscellaneous structural abnormalities,
and hyperdiploid. The inclusion into each
subgroup was based on a hierarchical
approach: molecular abnormalities with
adverse prognosis had precedence over
karyotypic changes with less-deﬁned
prognosis and the latter over ploidy. Pa-
tients without abnormalities and those
withisolated9p/p15-p16deletionsshowed
a relatively favorable outcome (median
disease-free survival [DFS], > 3 years).
Thet(9;22)/BCR-ABL,t(4;11)/MLL-AF4,t(1;
19)/E2A-PBX1 deﬁned a group with dis-
mal prognosis (median DFS, 7 months),
whereas 6q deletions, miscellaneous ab-
errations, and hyperdiploidy predicted an
intermediate prognosis (median DFS, 19
months). This study highlights the impor-
tance of a combined cytogenetic-molecu-
lar proﬁling of adult ALL at presentation
as a critical independent determinant of
their outcome, providing further evidence
of the necessity of a risk-adapted thera-
peutic algorithm for an optimal manage-
ment of these patients. (Blood. 2005;105:
3434-3441)
© 2005 by TheAmerican Society of Hematology
Introduction
The analysis of the chromosome and genetic abnormalities that occur in
acute leukemias has provided relevant insights into the prognostic
signiﬁcance of these genetic lesions, which, in turn, become of potential
importance for the design of risk-adapted therapeutic strategies for
newly diagnosed cases. In the last decade, only a few studies have
analyzed the prognostic value of cytogenetic abnormalities in large
series of adult patients with acute lymphoblastic leukemia (ALL).1-5
Although there is general agreement on the unfavorable clinical
outcome of patients withALL with t(9;22) or t(4;11) abnormalities, the
prognostic signiﬁcance of other cytogenetic abnormalities is still de-
bated. This may be attributed to the well-known technical difﬁculties
associated with chromosome analysis in ALL, the frequent overlap of
numerical and structural changes confounding the prognostic
signiﬁcance of the single anomaly, and the low frequency of certain
karyotypic changes.6,7 In addition, it should be considered that
most studies have focused on patients undergoing different treat-
ment modalities.1,3,5
Over the last 2 decades, it has become evident that molecular
investigations are a useful integration of cytogenetic analysis,
allowing the detection of molecular alterations in cases with
apparently normal or failed karyotype.8,9 Therefore, an integrated
cytogenetic-molecular approach seems the most appropriate tool
for an accurate genetic characterization of patients withALL at the
onset of the disease.
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center Gruppo Italiano Malattie Ematologiche dell’Adulto
(GIMEMA) 0496 study, started in 1996, provided for all adult
patients withALLentering the protocol a multiparametric diagnos-
tic approach including conventional cytogenetics and molecular
analysis for the following gene rearrangements: BCR-ABL, MLL-
AF4, E2A-PBX1, TEL-AML1, MLL, and p15 and p16 deletion.This
effort aimed at a careful characterization of the genetic lesions
occurring in adult ALL and at evaluating their prognostic signiﬁ-
cance in a large cohort of patients treated homogeneously.
Patients, materials, and methods
The GIMEMAALL 0496 protocol, which began in October 1996 and was
closed in September 2000, contemplated a central handling and biologic
investigation of bone marrow (BM) or peripheral blood (PB) samples of the
enrolled patients at presentation including conventional cytogenetics,
Southern blot and reverse transcription-polymerase chain reaction (RT-
PCR), and multidrug resistance (MDR1) expression. Samples were sent by
overnight dispatch to the laboratories of the Department of Cellular
Biotechnologies and Hematology, University “La Sapienza” of Rome; the
speciﬁc investigations were performed at the same center, at the Depart-
ment of Clinical and Biological Sciences, “S. L. Gonzaga” Hospital,
Orbassano, University of Turin, at the Hematology and Bone Marrow
Transplantation Unit, University of Perugia, at the CEINGE and Depart-
ment of Biochemistry and Medical Biotechnologies, University “Federico
II” of Naples, and at the Department of Biomedical Science, Hematology
Unit, University of Ferrara, all in Italy.
All patients were treated according to the ALL 0496 protocol, which is
derived from theALLVR589 regimen10 and included patients aged 16 to 60
years with a diagnosis of ALL, with the exclusion of L3 B-cell ALL
(B-ALL). The study was approved by the Institutional Review Board of the
Department of Cellular Biotechnologies and Hematology, University “La
Sapienza” of Rome. Informed consent was provided according to the
Declaration of Helsinki. The protocol design has been described else-
where11; in summary it comprised an induction period including high-dose
daunorubicin, a consolidation with high-dose ara-C, chemoprophylaxis and
radioprophylaxis of central nervous system involvement, and periodic
reinductions over a 3-year maintenance period. Patients positive for
Philadelphia chromosome (Ph) achieving complete remission (CR) were
treated according to the HAM protocol that included high-dose ara-C (3
g/m2/12 h for 4 days) and mitoxantrone (10 mg/m2/24 h for 3 days)
followed by allogeneic or autologous hemopoietic stem cell transplantation
based on the availability of an HLA-identical sibling.12
Cytology and immunology
The immunophenotype of ALL patients was performed by the referring
centers on BM or PB samples at diagnosis. The reactivity with monoclonal
antibodies directed against lymphoid and myeloid-associated antigens
(TdT, HLA-DR, CD19, CD10, CD20, CyIg, CD2, CD5, CD7; CD3, CD13,
CD33, CD14, CD34) was evaluated by ﬂow cytometry. Fixed cytocentri-
fuge preparations were used for the detection of TdT and CyIg chains by
immunocytochemical staining. The results were reviewed by the GIMEMA
biologic committee. The surface markers were considered positive when
20% or more of the blasts expressed the antigen; intracytoplasmic
positiveness was based on 10% or more reactive blasts. The immunologic
deﬁnition in B- and T-lineage ALL was based on the criteria deﬁned by the
European Group for the Immunological Characterization of Leukemias.13
Cytogenetic analysis
Cytogenetic analyses were performed in 3 referral centers (Rome, Ferrara,
and Perugia) on direct and 24-hour cultured preparations of BM or PB cells
(or both) without stimulation. GTG-banding chromosomes were classiﬁed
according to the International System for Human Cytogenetic Nomencla-
ture.14 A successful cytogenetic analysis required the detection of at least 2
or more cells with the same structural change or chromosomal gain, 3 or more
cells with the same chromosomal loss, or at least 20 metaphases without clonal
changes.However,inlessthan10%ofcasesclassiﬁedasnormal,10to19mitotic
ﬁgures could be analyzed. A central karyotype review was also performed in
difﬁcult cases. Each patient was classiﬁed hierarchically in different subgroups
on the basis of the cytogenetic abnormality; in particular, karyotypic aberrations
with known adverse prognostic signiﬁcance as t(9;22), t(4;11), t(1;19) took
precedenceoverotherswithlessdeﬁnedprognosticvalue,asdel(6q)anddel(9p).
If none of these was identiﬁed, patients having structural aberrations with or
without numerical changes not exceeding one chromosome gain or loss were
assigned to the miscellaneous group, whereas patients carrying numerical
aberrations only were assigned to the hyperdiploid group. Patients without
karyotypic anomalies were included in the normal group.
DNA analysis
High-molecular-weight DNA was extracted from Ficoll-Hypaque–isolated
mononuclear cells, digested to completion with EcoRI, HindIII, or BglII
restriction endonucleases, size-fractionated by electrophoresis through
0.8% agarose gels, denatured, and transferred to nitrocellulose membranes.
These DNAs were prehybridized for 2 to 4 hours at 42°C in a solution
containing 50% deionized formamide, 5  Denhardt solution, and 100
g/mL denatured salmon sperm and then hybridized at 42°C for 16 to 18
hours in the same solution with the denatured p16 exon 2 probe previously
labeled with 32P by the random priming technique.11 Filters were washed at
room temperature for 10 minutes in 0.2  standard saline citrate/0.1%
sodium dodecyl sulfate and at 50°C for 15 to 20 minutes in the same
solution. Filters were then exposed for 2 to 8 days at 80°C for
autoradiography using intensifying screens.
The B859 probe previously described, which explores the MLL
breakpoint region at chromosome 11q23, was also used to study the
conﬁguration of this gene in ALL patients.15 In addition to the detection of
rearrangements at this locus, this probe served as control for the assessment
of the DNAamount present in the ﬁlters. The genomic deletions of the p15
and p16 genes were evaluated in 211 patients.
RT-PCR
Total RNA was extracted from BM or PB mononuclear cells collected at
diagnosis and cryopreserved in guanidinium isothiocyanate, according to
the method of Chomczynski and Sacchi.16 To identify the most frequent
fusion genes in ALL—namely, MLL-AF4, MLL-ENL, the BCR-ABL p190
(e2a2) and p210 (b2a2, b3a2) isoforms, E2A-PBX1, TEL-AML1—we used a
multiplex RT-PCR strategy17 in 60 cases and the standardized RT-PCR
protocol deﬁned by the Biomed-1 Concerted Action in the remaining.18
Analyses were conducted in 3 referral centers (Rome, Turin, and Naples)
and centrally reviewed. Because the therapeutic program contemplated a
different postremission strategy for patients with BCR-ABL ALL, the
BCR-ABL fusion product detection was performed in all patients. The
presence of the MLL-AF4, E2A-PBX, and TEL-AML1 fusion transcripts was
investigated in 287, 162, and 162 cases, respectively.
MDR1 expression
MDR1 expression was assessed on BM or PB samples by depicting the
leukemic cells with the MRK16 antibody (Kamiya Biomedical, Seattle,
WA), which reacts with a cell surface epitope of the P-glycoprotein (P-gp)
170, as previously reported.19 Flow cytometry was used to measure the
ﬂuorescence intensity of the leukemic samples and of the MDR1 cell lines
used as controls in the analysis standardization. Differences in ﬂuorescence
intensity were evaluated using the Kolmogorov-Smirnov statistic test (D).20
According to the study priority, 250 cases were analyzed in one referral
laboratory in Rome.
Statistical analyses
Comparison of pretreatment characteristics on CR rate was carried out
using the 2 test or Fisher exact test. The relationship of the outcome with
age, white blood cells (WBCs), phenotype, MDR, and cytogenetic-
molecular classiﬁcation was analyzed using the logistic and Cox regression
models.21 In the multivariate analysis, the classiﬁcation in 2 cytogenetic-
molecular risk groups was tested with the following variables: age and
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as expression of B versusTmarkers; MDR expression was dichotomized as
present ( 0.05) or absent. The probability of disease-free survival (DFS)
and overall survival (OS) was calculated using the Kaplan and Meier
method22 and the prognostic value of potential factors was analyzed using
the log-rank test with stratiﬁcation for risk group.23
Results
Cytogenetics
Conventional cytogenetics was performed on 378 of 414 cases
centrally processed, due to inadequate samples for cytogenetic
analysis (6 cases) or missing cytogenetic samples (30 cases). An
evaluable karyotype was obtained in 282 cases (75%) and an
abnormal clone was detected in 168 (60%). Cases with a deﬁned
karyotype were classiﬁed in different subgroups following the
hierarchical approach indicated (Table 1). Among cases with
structural changes, the subgroup with the t(9;22) translocation was
the largest (64 of 378; 16.9%). In this group, additional chromo-
somal changes were identiﬁed in 55% of the cases and included an
additional Ph (8 cases), 9p deletion (3 cases), and chromosomal
gain resulting in hyperdiploidy (3 cases). Patients with t(9;22) had
B-lineage ALL in all cases but one (a T-ALL) with expression of
the CD34 and CD10 antigens in more than 90 of cases, a WBC
count more than 10  109/L in more than 60%, and an age older
than 30 years in 78% of cases.At(4;11) translocation was identiﬁed
in 18 patients (4.8%); 5 had additional structural anomalies that
included i(7q) (1 case) and del(6q) (1 case).At(1;19) translocation
was detected in 3 cases (0.8%); 2 had the unbalanced form and 1
the balanced form of the translocation; all cases showed additional
changes including in one instance a del(6q). Partial deletions of the
long arm of chromosome 6 were identiﬁed in 15 cases (4%); of
these,1hadthepresenceofaBCR-ABLrearrangementatthemolecular
level.AT-cell phenotype was found in 8 (57%) of 14 cases, and in 6 of
them the anomaly was present as isolated change. An isolated del(9p)
wasidentiﬁedin2cases,bothshowingaB-cellphenotype.Theother41
cases (10.8%) with an abnormal karyotype were combined to form the
miscellaneous group. The most common structural changes included in
this group were del(7q) (3 cases), del(5q) (2 cases), del(12p) or t(12p) (2
cases), t(10;14)(q24;q11) (2 cases), t(4;11)(q21;p15) (1 case), and 14q
abnormalities (5 cases). Numerical aberrations consisting in low hyper-
diploidy (47-50 chromosomes, 16 cases) and in high hyperdiploidy
(50 chromosomes, 9 cases) were identiﬁed in 25 patients (6.6%).
Finally, 114 cases (30.2%) without apparent structural or numerical
changes were recorded.
Molecular analysis
Molecular analyses were performed on 386 of 414 cases
centrally collected, owing to inadequate samples for molecular
investigation (6 cases) or absence of molecular abnormalities in
cases with missing cytogenetic samples (22 cases). BCR-ABL
fusion was detected in 102 of 386 cases (26.4%; Table 2). Of
these, 58 (57%) showed a p190, 23 (23%) a p210, 19 (19%) a
p190/210 fusion protein, and 1 a rare e1a3 fusion. AF4-MLL,
E2A-PBX1, and TEL-AML1 fusion genes were identiﬁed in 23
(8%) of 287, 6 (3.7%) of 162, and 1 (0.6%) of 162 of the
investigated cases, respectively. A homozygous or hemizygous
loss of p15 or p16 genes (or both) was documented in 52
(24.6%) of 211 analyzed cases. Among the 52 deleted cases, 30
showed the deletion as an isolated anomaly. BCR-ABL (11
cases), E2A-PBX1 (1 case), and AF4-MLL (1 case) fusions
emerged as the molecular changes more frequently associated
with p15/p16 deletion. Of the 386 cases molecularly investi-
gated, 61 with molecular analysis negative for the presence of
fusion genes or p15-p16 deletion and inadequate cytogenetic
results (no mitosis or  10 analyzed cells with normal karyo-
type) were considered as not evaluable.
Integrated cytogenetic and molecular classiﬁcation
Considering the cases having both conventional cytogenetics (282
cases) or molecular analysis (325 cases) successfully performed, a
total of 325 patients with a deﬁned genetic proﬁle were hierarchi-
cally classiﬁed in the following subgroups: normal, BCR-ABL/t(9;
22), MLL-AF4/t(4;11), E2A-PBX1/t(1;19), 6q deletions, miscella-
neous, hyperdiploid, 9p and/or p15 and/or p16 deletions.
This integrated cytogenetic-molecular approach ensures a more
precise categorization of patients with respect to the presence or
absence of distinct genetic alterations.
The frequency of each cytogenetic-molecular subgroup and
their associated biologic and clinical features are presented in
Tables 3 and 4. With respect to previously cytogenetic-based
classiﬁcations, this classiﬁcation system allowed us to delineate,
in particular, 3 subgroups of patients: namely, normal, 9p/p15-
p16 deletions, and hyperdiploid, as much as possible free from
confounding genetic abnormalities. Compared with the other
cytogenetic-molecular subgroups, patients included in the nor-
mal subgroup showed more frequently an age younger than 30
years (59.3% versus 40.6%; P  .003) and a WBC count lower
than 30  103/L (72.1% versus 56.1; P  .009). As for the
del(6q) subgroup, patients included in the group with isolated
cytogenetic or molecular 9p/p15-p16 abnormalities had more
frequently a T-cell lineage ALL than patients of the other
subgroups (57.1% versus 36.7%, P .001). The hyperdip-
loid group showed a CD10 B-lineage ALL more frequently
than the other groups (58.3% versus 32.2%; P  .009) and
tended to have more frequently a WBC count lower than
30  103/L (76% versus 59%), as in the normal subgroup.
Treatment results
Of the 325 patients registered and eligible for the study who could
be considered for the integrated cytogenetic-molecular classiﬁca-
tion, 317 started the induction treatment and 294 were evaluable for
Table 1. Distribution by cytogenetic hierarchical classiﬁcation
Groups No. cases % of cases
Normal 114 30.2
del(9p) 2 0.5
del(6q) 15 4.0
Hyperdiploid 25 6.6
Miscellaneous structural abnormalities 41 10.8
t(9;22) 64 16.9
t(4;11) 18 4.8
t(1;19) 3 0.8
Failed 96 25.4
Total 378 100.0
Table 2. Distribution by molecular abnormalities
Type of transcript or
gene rearrangement
No. abnormal cases/ no. analyzed
cases (%)
BCR-ABL 101/386 (26.2)
MLL-AF4 23/287 (8.0)
TEL-AML1 1/162 (0.6)
E2A-PBX1 6/162 (3.7)
p15/p16 deletion 52/211 (24.6)
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overall DFS was 31% at 5 years (95% CI, 24.4%-37.0%; Figure 1).
The OS at 5 years was 31% (95% CI, 25.6%-36.3%; Figure 2). The
overall clinical outcome of the patient population considered for
the cytogenetic-molecular classiﬁcation did not differ from that of
theotherpatientsenrolledinthetrial(CRrate,80%;DFSandOSat
5 years, 33% [95% CI, 27.7%-37.9%], and 33% [95% CI,
28.3%-37.3%], respectively).
Table 3. Distribution of 386 ALL cases according to conventional cytogenetic and cytogenetic-molecular classiﬁcation
Cytogenetic group Normal
Cytogenetic-molecular groups, no.
t(9;22)/
BCR-
ABL
t(4;11)/
AF4-
MLL
t(1;19)/
E2A-PB
XI del(6q) Hyperdiploid Miscellaneous
del(9p)/
p15-
p16
Not
evaluable Total
Normal 86 4 3 2 0 0 1* 18 0 114
t(9;22) 0 64† 0 0 0 0 0 0 0 64
t(4;11) 0 0 18‡ 0 0 0 0 0 0 18
t(1;19) 0 0 0 3‡ 0 0 0 0 0 3
del(6q) 0 1 0 0 14 0 0 0 0 15
Hyperdiploid 0 0 0 0 0 25 0 0 0 25
Miscellaneous 0 2 2 1 0 0 36 0 0 41
del(9p) 0 0 0 0 0 0 0 2 0 2
Not evaluable 0 25 1 1 0 0 0 8 61 96
Not done 0 6 0 0 0 0 0 2 0 8
Total 86 102 24 7 14 25 37 30 61 386
*TEL-AML1.
†One case with positive ﬂuorescence in situ hybridization and negative RT-PCR.
‡One case missing molecular analysis.
Table 4. Pretreatment characteristics of 325 genetically deﬁned patients by cytogenetic-molecular groups
Total
Cytogenetic-molecular groups
Normal
t(9;22)/
BCR-ABL
t(4;11)/
AF4-MLL
t(1;19)/
E2A-PBX1 del(6q)
del(9p)/
p15-p16
Pseudo-
diploid Hyperdiploid
Total 325 86 102 24 7 14 30 37 25
Sex, no. (%)
Male 194 (60) 51 (59) 54 (53) 13 (54) 3 (43) 11 (78) 24 (80) 22 (59) 16 (61)
Female 131 (40) 35 (41) 48 (47) 11 (46) 4 (57) 3 (22) 6 (20) 15 (41) 9 (39)
Median age, y (range) 31 (14-60) 26 (15-58) 42 (16-60) 39 (15-59) 22 (15-58) 27 (18-57) 29 (14-59) 23 (15-59) 22 (15-53)
Age, no. (%)
Younger than 30 y 148 (46) 51 (59) 22 (22) 7 (29) 6 (86) 8 (57) 15 (50) 25 (68) 14 (56)
31 to 50 y 124 (38) 29 (34) 51 (50) 14 (58) 0 (0) 5 (36) 10 (33) 7 (19) 8 (32)
51 to 60 y 53 (16) 6 (7) 29 (28) 3 (13) 1 (14) 1 (7) 5 (17) 5 (13) 3 (12)
WBC counts, no. (%)
10  109/L or less 132 (41) 49 (57) 36 (35) 3 (12.5) 3 (43) 4 (29) 10 (33) 14 (38) 13 (52)
10  109/L to 30  109/L 64 (20) 13 (15) 17 (17) 5 (21) 3 (43) 4 (29) 7 (23) 9 (24) 6 (24)
30  109/L to 50  109/L 32 (10) 8 (9) 12 (12) 3 (12.5) 0 2 (14) 3 (10) 2 (5) 2 (8)
50  109/L to 100  109/L 43 (13) 6 (7) 19 (19) 5 (21) 0 1 (7) 4 (14) 7 (19) 1 (4)
100  109/L or more 53 (16) 10 (12) 17 (17) 8 (33) 1 (14) 3 (21) 6 (20) 5 (14) 3 (12)
Phenotype, no. (%)
B 266 (82) 66 (77) 101 (99) 24 (100) 7 (100) 6 (43) 19 (63) 25 (68) 18 (72)
T 59 (18) 20 (23) 1 (1) 0 0 8 (57) 11 (37) 12 (32) 7 (28)
CD10 status, no. (%)
Positive 206 (66) 52 (64) 92 (93) 0 (0) 7 (100) 6 (46) 19 (63) 20 (57) 10 (42)
Negative 107 (34) 29 (36) 7 (7) 24 (100) 0 (0) 7 (54) 11 (37) 15 (43) 14 (58)
Not done 12 5 3 0 0 1021
CD13 status, no. (%)
Positive 77 (26) 23 (29) 33 (35) 0 (0) 0 (0) 2 (15) 1 (4) 10 (29) 8 (38)
Negative 222 (74) 55 (71) 62 (65) 24 (100) 6 (100) 11 (85) 26 (96) 25 (71) 13 (62)
Not done 26 8 7 0 1 1324
CD33 status, no. (%)
Positive 67 (22) 19 (24) 33 (35) 0 (0) 0 (0) 0 (0) 2 (7) 7 (20) 6 (26)
Negative 235 (78) 59 (76) 62 (65) 23 (100) 7 (100) 13 (100) 26 (93) 28 (80) 17 (74)
Not done 23 8 7 1 0 1222
CD34 status, no. (%)
Positive 223 (72) 57 (71) 92 (95) 10 (41) 0 (0) 8 (57) 14 (48) 24 (76) 18 (75)
Negative 86 (28) 23 (29) 5 (5) 14 (59) 7 (100) 6 (43) 15 (52) 10 (24) 6 (25)
Not done 16 6 5 0 0 0131
MDR, no. (%)
Yes 57 (23) 15 (24) 16 (21) 2 (11) 1 (14) 1 (9) 7 (26) 8 (27) 7 (37)
No 193 (87) 47 (76) 59 (79) 17 (89) 6 (86) 10 (91) 20 (74) 22 (73) 12 (63)
Not done 75 24 27 5 0 3376
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The MDR protein expression was assessed by MRK16 bind-
ing. MDR1 expression was detected in 57 (23%) of the 250
analyzed cases.
Prognostic value of the integrated molecular-cytogenetic
classiﬁcation in ALL patients at presentation
Excluding patients not evaluable for response to induction, 294
of 325 cases could be assessed for their clinical outcome. No
signiﬁcant differences among the 8 cytogenetic-molecular sub-
groups were observed in terms of CR rate (P  .238). In
contrast, on the basis of the median DFS, 3 prognostic groups
could be distinguished by the presence of speciﬁc cytogenetic-
molecular abnormalities. Cases with normal karyotype and
isolated 9p/p15-p16 deletions are suggestive of having a rela-
tively better outcome (median DFS,  3 years) and were
considered as a “standard-risk” group, whereas patients with
t(9;22), t(4;11), and t(1;19) showed an adverse prognosis
(median DFS, 7 months) and were comprised in an “adverse-
risk” category. Patients with del(6q), miscellaneous abnormali-
ties, and hyperdiploidies exhibited an intermediate outcome
(median DFS, 19 months) and were included in the “intermediate-
risk” group. In univariate analysis, with respect to the DFS
probability at 2 years, patient stratiﬁcation on the basis of
cytogenetic-molecular features was signiﬁcantly associated with
outcome (P  .001; Figure 3). In a multivariate analysis model
including age, WBC count, MDR, and immunophenotype,
patients in the “high-risk” group had a statistically signiﬁcant
lower probability to be alive without disease recurrence after 2
years from remission, compared to the “intermediate-risk”
(hazard ratio [HR] 2.00; P  .02), and patients in the “standard-
risk” showed a signiﬁcantly higher probability of being alive in
remission compared to those in the intermediate-risk group (HR
0.55; P  .04; Table 6). After a more prolonged follow-up, the
differences in outcome between the favorable and intermediate
groups tend to erode, becoming comparable at 5 years (Figure 3
and Tables 7-9).
Discussion
Despite the efforts to identify at the onset of the disease subgroups
of adult patients with ALL with a different prognostic likelihood,
the predictive value of the risk models so far proposed is still
limited. Considering that cytogenetic and molecular features are
among the most important factors for predicting outcome, we
hereby propose a risk classiﬁcation system based on an integrated
cytogenetic-molecular characterization of a large series of patients
with adult ALL enrolled in the GIMEMA ALL 0496 trial and
studied prospectively at presentation. This systematic approach
ﬁrst allowed us to decrease the number of cases with failed
cytogenetics (from 25% to 16%) or normal karyotype (from 29.5%
to 22%) through the detection of molecular lesions not identiﬁed by
conventional cytogenetics and vice versa, and second, to depict 8
different cytogenetic-molecular subgroups as much as possible
homogeneous for deﬁned genetic abnormalities, such as BCR-ABL
or t(9;22), MLL-AF4 or t(4;11), p15 and/or p16 deletion or del(9p),
and so forth (Table 5). Within the normal karyotype group, 28 of
114 patients had molecular anomalies missed by conventional
cytogenetics. The most frequently detected were p15 and p16
deletions (18 of 28 cases), t(9;22) (4 of 28 cases), and t(4;11) (3 of
28 cases). This conﬁrms previous observations that most of the p15
and p16 deletions are not detected by conventional cytogenet-
ics.24,25 In the group with failed cytogenetic analysis, 35 of 96 cases
were found to harbor molecular abnormalities consisting of BCR-
ABL (25 of 35), AF4-MLL (1 of 35), and E2A-PBX1 (1 of 35)
rearrangements, and p15 or p16 deletions (8 of 35). Considering the
patients with normal or not evaluable cytogenetics, most molecular
abnormalities are restricted to the failed cytogenetic group (77.4%
versus 22.6%; P .001).
When the DFS probability at 2 years is considered as an early
prognostic end point, the cytogenetic-molecular subgroups delineated in
the present study allow prediction of a different clinical outcome
likelihood. Cases with no abnormalities or with 9p/p15 and/or p16
deletions have a signiﬁcantly higher DFS probability, as shown in
Figure 3. The prognostic signiﬁcance of a normal karyotype has been
seldom estimated in adultALLand varies in different series. The results
of our study are consistent with the outcome of a series of 443 adult
Figure 1. DFS of 232 patients obtained CR and considered in the integrated
cytogenetic-molecular classiﬁcation.
Figure 2. OS of 325 patients considered for the integrated cytogenetic-
molecular classiﬁcation.
Table 5. Flow chart of the patients included in the GIMEMA
0496 protocol
Clinical
trial
Central
handling
Evaluable integrated
cytogenetic-molecular
classiﬁcation
No. patients eligible for the study 498 414 325
No. patients who started induction 490 408 317
No. patients evaluable for response 455 380 294
No. RC (%) 363 (80) 303 (80) 232 (79)
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tologique (GFCH),3 which found the normal karyotype group to be
associated with a better prognosis (median event-free survival [EFS], 24
months; EFS 44%) than the abnormal karyotype group (P.001) in
B-lineage ALL. This ﬁnding was not conﬁrmed by the Medical
Research Council (MRC) UKALL XA trial,4 which showed that DFS
for patients with a diploid karyotype was comparable with the poor-
outcome categories. This result, however, could be due to the presence
of poor-risk genetic lesions missed by conventional cytogenetics,
because in this study molecular investigations were not performed. The
frequency of normal karyotypes has been reported to range between
16% and 34% for adult ALL patients; clinical features associated with
this subgroup include a median age ranging between 30 and 44 years, a
medianWBCcountbetween10and30 109/L,andaT-cellphenotype
in 18% to 38% of cases.1-5,26 In the present series, the subgroup with
normal karyotype represented 27% of cases and showed more fre-
quently than the abnormal cytogenetic-molecular subgroups a young
age (27 years; range, 14-58 years), a low WBC count (6.8 109/L;
range, 0.6-700 109/L), whereas the prevalence of T-cell phenotype
was similar to that of the other groups (23%).
In addition to normal karyotype, the standard-risk group
included cases carrying abnormalities of the short arm of chromo-
some 9, including p15 and p16 deletions. These abnormalities have
been found in approximately 10% of childhood ALL with a higher
percentage in T-ALL and in 5% to 16% of adults.27-31 Frequently,
9p deletions have been associated with other abnormalities, in most
cases the t(9;22) translocation, and are considered a secondary
change.5,24,30 In our series, 9p, p15 and/or p16 deletions were found
in 52 (25%) of 211 analyzed cases emerging as the most frequent
molecular abnormalities after BCR-ABL. In 30 cases, 19 with B-
and 11 with T-cell phenotype, this group of anomalies was present
as an isolated change, suggesting that it may be considered as a
primary change in ALL. Comparing this group with the 22 cases
carrying 9p abnormalities in addition to other changes consisting of
a t(9;22) (11 cases), other structural changes included in the
pseudodiploid subgroup (7 cases), a del(6q) (2 cases), a t(1;19) (1
case), and a t(4;11) (1 case), patients with isolated 9p/p15 and/or
p16 deletion showed a similar median age (27 versus 29 years), but
a lower median WBC count (21 versus 46  109/L). In a pediatric
series treated with a Children’s Cancer Group risk-adjusted proto-
col, Heerema et al27 reported that deletions of 9p were associated
with an adverse prognosis in B-lineage ALL and, in the homozy-
gous form, also in T-ALL. This ﬁnding has been conﬁrmed by
Carter et al,32 who reported that homozygous and hemizygous
deletions of p16 are independent predictors of relapse. Disagree-
ment still exists about the correlation with prognostic and immuno-
phenotypic features of 9p abnormalities in adult ALL. Fizzotti et
al33 found a signiﬁcant relationship between p16 deletion and a
subset of ALL with features of aggressive disease (high leukemic
cellmassandhighWBCcounts),butnodifferencesbyimmunophe-
notype. Indeed, the GFCH reported no impact on prognosis and no
signiﬁcant correlation with B- or T-lineage ALL.3 Similar ﬁndings
were observed by Faderl et al,24 who reported no difference in the
outcome of patients with homozygous p15 and p16 gene deletions
with respect to patients with no deletions or loss of only one allele.
The correlation of 9p abnormalities with an adverse prognosis may
depend on their frequent association with additional karyotypic
changes, often consisting in poor-risk aberrations such as t(9;22),
t(4;11), or complex abnormalities. Conversely, our study suggests
that the p15 and/or p16 deletions, when present as an isolated
change, are not associated with a high risk of relapse at short term.
The intermediate prognostic category included patients with
del(6q), cases with diploid karyotype, and a miscellaneous group of
other structural changes not encompassed by the other 2 risk
groups, which were too infrequent to be assigned a prognostic
signiﬁcance in their own right, as well as cases with only numerical
acquisitions. Partial deletions of the long arm of chromosome 6
Table 6. Multivariate analysis for DFS at 2 years
Variable P value
Hazard
ratio
95% hazard ratio
conﬁdence limits
WBCs,  109/L* 0.0479 1.002 1.000 1.003
Age, y† 0.2061 1.010 0.994 1.026
Phenotype, B or T 0.2924 1.385 0.755 2.538
MDR, negative or positive 0.7815 0.928 0.546 1.575
Cytogenetic-molecular risk group
Intermediate vs standard 0.0428 0.552 0.311 0.981
Intermediate vs high 0.0231 2.006 1.100 3.659
*Range, 0.5-848  109/L.
†Range, 16-60 years.
Figure 3. DFS by univariate analysis. DFS according to (A) cytogenetic subgroups,
(B) cytogenetic-molecular subgroups, and (C) cytogenetic-molecular risk groups.
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ranging between 6% and 10% of patients, and an association with a
favorable prognosis. In adults, too few cases have been reported so
far to allow deﬁnitive clinical and biologic correlations. Our study
highlights the preferential correlation of this anomaly with a T-cell
phenotype, especially when it is present as isolated change, as
reported elsewhere.11 Moreover, the result of our analysis makes
previous not unfavorable prognostic suggestions somewhat ques-
tionable, on the basis of the median DFS of 19 months recorded in
the del(6q) subgroup. The hyperdiploid group, which includes 9
cases (32%) with so-called “high” hyperdiploidy ( 51 chromo-
somes), accounts for 8% of successfully investigated cases, in line
with what so far is described in adult ALL. More than 50% of the
hyperdiploid cases described in the literature were of B-cell
phenotype, were younger than 30 years, and a normal WBC
count.3,4The clinical outcome of patients with hyperdiploidy varies
in different series, being more favorable in children than in adults,
where a poor outcome has been repeatedly reported.3,5,26 Similarly,
in the present study a median DFS of 19 months has been recorded
in the hyperdiploid group, despite the absence of unfavorable
structural changes, indicating that adults may not enjoy the good
prognosis reported in children. Adverse risk features, which may
correlate with an unfavorable outcome, such as WBC count more
than 30  109/L and age older than 30 years,34,35 were observed in
this group in 24% and 44% of cases, respectively.
The t(9;22), t(4;11), and t(1;19) translocations deﬁned a cytoge-
netic-molecular group with unfavorable outcome. With respect to
the ﬁrst 2 abnormalities, our data are consistent with what is
reported by several groups in terms of poor outcome.3-5 The
association with a poor prognosis of the t(1;19) translocation,
which in this series was found in 4% of cases, is still debated. In
pediatric ALL, where this aberration is more common (8%),
improved outcome has been obtained with a more intensiﬁed
treatment.36 In adults, the GFCH3 described 11 cases, of which 9
failed therapy within 12 months from diagnosis; conversely, the
MRC UKALLXA4 did not conﬁrm the adverse outcome, reporting
a 3-year DFS of 54% in 10 patients, 4 of them undergoing bone
marrow transplantation. In the present study, t(1;19) characterizes a
subset of relatively young patients with CD10, often CyIg,
B-lineage ALL who do not express CD34 and myeloid associated
antigens. Despite the high CR rate, this anomaly was associated
with early treatment failure in 5/7 patients.37
Our study emphasizes the feasibility of a combined cytogenetic-
molecular classiﬁcation of adult patients withALLin the context of
a multicenter clinical trial. At 2 years, the stratiﬁcation in 3 risk
groups derived from this approach emerges, in univariate and
multivariate analysis, as a variable signiﬁcantly associated with
DFS probability. Although at 5 years the favorable and intermedi-
ate groups had an overall comparable outcome, this model
highlights a category of patients with at least 2 years of relatively
favorable outcome during which, on the basis of the presence of
minimal residual disease, the impact of consolidative treatment
strategies including newer drugs should be evaluated.
In conclusion, our data indicate that a combined broad cytogenetic-
molecular classiﬁcation of adults with ALL at presentation provides a
framework that clearly distinguishes groups of patients with a different
likelihood of relapse and that, in the context of multicenter protocols,
this integrated approach is essential for the design of a risk-adapted
therapeutic algorithm. The challenge of future trials will be to further
extend the number of cytogenetic-molecular proﬁled cases by using
noveltechniques,suchasspectralkaryotypingandcomparativegenomic
hybridization, as well as to complement the genetic screening with other
parameters in order, ultimately, to permit a more reﬁned and targeted
clinical management.
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Gugliotta; Ospedale S Eugenio, Roma, Sergio Amadori; Universita `d i
Sassari, Maurizio Longinotti; Ospedale S Martino, Genova, Gino
Santini; Dipartimento di Medicina Interna, Universita ` di Genova,
Riccardo Ghio; Ospedale A Di Summa Brindisi, Giovanni Quarta;
Ospedale A Sclavo, Siena, Francesco Lauria; Ospedale Maggiore, Lodi,
Giulio Nalli; Ospedale E Morelli, Sondalo, Renzo Epis; CRO Aviano,
Umberto Tirelli; Universita ` di Palermo, Vincenzo Abbadessa; Ospedale
S Salvatore, Pesaro, Giuseppe Visani; Ospedale S Croce e Carle, Cuneo,
Andrea Gallamini; Ospedale SS Annunziata, Taranto, Patrizio Mazza;
Ospedale Maggiore della Carita `, Novara, GiancarloAvanzi.
Table 7. Univariate analysis for DSF according to
cytogenetic subgroups
, y Median, % 95% CI, y No. patients No. events
del(9p) Not reached* — — 2 0
Normal 2.8 49 38.2-60.2 83 48
Hyperdiploid 1.6 50 28.1-71.9 20 12
del(6q) 1.6 45 16.0-74.9 11 8
Miscellaneous 1.3 48 30.1-66.5 29 17
t(1;19) 0.8 33 0-86.7 3 2
t(9;22) 0.6 50 34.1-65.9 38 34
t(4;11) 0.4 50 25.5-74.5 16 12
*del(9p) 100% at 4 years.
Table 8. Univariate analysis for DSF according to cytogenetic-
molecular subgroups
, y Median, % 95% CI, y No. patients No. events
del(9p)/p15-p16 4.0 45 22.0-68.0 22 12
Normal 2.9 50 37.7-63.1 63 35
Hyperdiploid 1.6 50 28.1-71.9 20 12
del(6q) 1.6 50 19.0-81.0 10 7
Pseudodiploid 1.3 50 30.8-69.2 26 15
t(1;19)/E2A-PBX1 0.6 43 6.2-79.5 7 5
t(9;22)/BCR-ABL 0.6 49 36.9-61.6 63 53
t(4;11)/AF4-MLL 0.4 48 26.3-69.0 21 17
Table 9. Univariate analysis for DSF according to cytogenetic-
molecular risk groups
, y 95% CI, y No. patients No. events
Standard 3.2 38.6-60.6 85 47
Intermediate 1.6 36.9-63.1 56 34
High 0.62 39.2-59.7 91 75
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